TRPV1: a therapeutic target for novel analgesic drugs?
- PMID: 16996800
- DOI: 10.1016/j.molmed.2006.09.001
TRPV1: a therapeutic target for novel analgesic drugs?
Abstract
The vanilloid receptor TRPV1 is now recognized as a molecular integrator of painful stimuli ranging from noxious heat to endovanilloids in inflammation. Pharmacological blockade of TRPV1 represents a new strategy in pain relief. TRPV1 antagonists are expected to prevent pain by silencing receptors where pain is generated rather than stopping the propagation of pain, as most-traditional pain killers do. This hypothesis has already being tested in the clinic by administering small molecule TRPV1 antagonists (e.g. GlaxoSmithKline SB-705498) for migraine and dental pain. Paradoxically, in some murine models of chronic pain, TRPV1-deficient mice exhibit more pain-related behavior than their wild-type littermates, indicating that the understanding of TRPV1 in pain is still incomplete. Moreover, there is mounting evidence to suggest the existence of functional TRPV1 both in the brain and in various non-neuronal tissues. The biological role of these receptors remains elusive, but their tissue distribution clearly indicates that they are involved in many more functions than just pain perception. Here, we review the potential therapeutic indications and adverse effects of TRPV1 antagonists.
Similar articles
-
Brain TRPV1: a depressing TR(i)P down memory lane?Trends Pharmacol Sci. 2008 Dec;29(12):594-600. doi: 10.1016/j.tips.2008.09.004. Epub 2008 Oct 22. Trends Pharmacol Sci. 2008. PMID: 18947889
-
The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.Nat Rev Drug Discov. 2007 May;6(5):357-72. doi: 10.1038/nrd2280. Nat Rev Drug Discov. 2007. PMID: 17464295 Review.
-
TRPV1 antagonists: the challenges for therapeutic targeting.Trends Mol Med. 2009 Jan;15(1):14-22. doi: 10.1016/j.molmed.2008.11.004. Epub 2008 Dec 25. Trends Mol Med. 2009. PMID: 19097938
-
Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons.Neuroscience. 2007 Aug 24;148(2):560-72. doi: 10.1016/j.neuroscience.2007.05.049. Epub 2007 Jul 25. Neuroscience. 2007. PMID: 17656027
-
Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.Brain Res Rev. 2009 Apr;60(1):267-77. doi: 10.1016/j.brainresrev.2008.12.006. Epub 2008 Dec 25. Brain Res Rev. 2009. PMID: 19150372 Review.
Cited by
-
Sumatriptan inhibits TRPV1 channels in trigeminal neurons.Headache. 2012 May;52(5):773-84. doi: 10.1111/j.1526-4610.2011.02053.x. Epub 2012 Jan 30. Headache. 2012. PMID: 22289052 Free PMC article.
-
Urothelial signaling.Auton Neurosci. 2010 Feb 16;153(1-2):33-40. doi: 10.1016/j.autneu.2009.07.005. Epub 2009 Aug 8. Auton Neurosci. 2010. PMID: 19666243 Free PMC article. Review.
-
TRP channels: a journey towards a molecular understanding of pain.Nat Rev Neurosci. 2022 Oct;23(10):596-610. doi: 10.1038/s41583-022-00611-7. Epub 2022 Jul 13. Nat Rev Neurosci. 2022. PMID: 35831443 Review.
-
Future aspects of botulinum neurotoxins.J Neural Transm (Vienna). 2008;115(4):567-73. doi: 10.1007/s00702-007-0758-9. Epub 2007 Jun 8. J Neural Transm (Vienna). 2008. PMID: 17557128 Review.
-
Multi-Functional Diarylurea Small Molecule Inhibitors of TRPV1 with Therapeutic Potential for Neuroinflammation.AAPS J. 2016 Jul;18(4):898-913. doi: 10.1208/s12248-016-9888-z. Epub 2016 Mar 21. AAPS J. 2016. PMID: 27000851 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
